View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
July 20, 2018updated 12 Jul 2022 1:13pm

Asana starts Phase llb trial of ASN002 for atopic dermatitis

Asana BioSciences has commenced the RADIANT Phase llb trial to investigate the efficacy, safety, tolerability, and pharmacokinetics of ASN002 to treat patients with moderate-to-severe atopic dermatitis (AD).

Asana BioSciences has commenced the RADIANT Phase llb trial to investigate the efficacy, safety, tolerability, and pharmacokinetics of ASN002 to treat patients with moderate-to-severe atopic dermatitis (AD).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The randomised, double-blind, placebo-controlled trial is expected to enrol around 220 adult patients diagnosed with chronic atopic dermatitis for at least six months with an eczema area and severity index (EASI) score of 16 or more.

The patients will also be required to have an investigator’s global assessment (IGA) score of three or greater, and a body surface area involving at least 10% at baseline.

As part of the trial, the enrolled patients will be randomly assigned to receive a 40mg, 60mg or 80mg once-daily dose of ASN002 or placebo for 12 weeks.

The trial’s primary outcome measure is the change in EASI score from baseline to week 12.

“We believe ASN002 is the first JAK inhibitor to report parallel improvements in clinical, histological and molecular parameters in AD skin lesions.”

Its secondary endpoints are IGA, pruritus scores (NRS), patient-oriented eczema measure (POEM) and dermatology life quality index (DLQI).

The trial is set to be carried out at various sites in the US, Canada and Germany.

Asana BioSciences founder and CEO Dr Sandeep Gupta said: “We believe ASN002 is the first JAK inhibitor to report parallel improvements in clinical, histological and molecular parameters in AD skin lesions.

“These compelling data indicate the potential of ASN002 as an important treatment option for patients with moderate-to-severe atopic dermatitis, as well as its potential applications for other dermatologic and auto-immune diseases.”

AD is a common inflammatory skin disease that affects both children and adults.

The disease is characterised by pruritus (itch), a chronically relapsing course, and often affects a personal or family history of atopic diseases.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena